Breast Cancer Brain Metastases: Clonal Evolution in Clinical Context
1
The University of Queensland (UQ), UQ Centre for Clinical Research, Herston, Queensland 4029, Australia
2
QIMR Berghofer Medical Research Institute, Herston, Queensland 4006, Australia
3
Pathology Queensland, Royal Brisbane Women’s Hospital, Herston, Queensland 4029, Australia
4
UQ School of Medicine, Herston, Queensland 4006, Australia
*
Author to whom correspondence should be addressed.
Academic Editor: Dario Marchetti
Int. J. Mol. Sci. 2017, 18(1), 152; https://doi.org/10.3390/ijms18010152
Received: 8 November 2016 / Revised: 22 December 2016 / Accepted: 27 December 2016 / Published: 13 January 2017
(This article belongs to the Special Issue Brain Metastasis 2016)
Brain metastases are highly-evolved manifestations of breast cancer arising in a unique microenvironment, giving them exceptional adaptability in the face of new extrinsic pressures. The incidence is rising in line with population ageing, and use of newer therapies that stabilise metastatic disease burden with variable efficacy throughout the body. Historically, there has been a widely-held view that brain metastases do not respond to circulating therapeutics because the blood-brain-barrier (BBB) restricts their uptake. However, emerging data are beginning to paint a more complex picture where the brain acts as a sanctuary for dormant, subclinical proliferations that are initially protected by the BBB, but then exposed to dynamic selection pressures as tumours mature and vascular permeability increases. Here, we review key experimental approaches and landmark studies that have charted the genomic landscape of breast cancer brain metastases. These findings are contextualised with the factors impacting on clonal outgrowth in the brain: intrinsic breast tumour cell capabilities required for brain metastatic fitness, and the neural niche, which is initially hostile to invading cells but then engineered into a tumour-support vehicle by the successful minority. We also discuss how late detection, abnormal vascular perfusion and interstitial fluid dynamics underpin the recalcitrant clinical behaviour of brain metastases, and outline active clinical trials in the context of precision management.
View Full-Text
Keywords:
breast cancer; brain metastases; clonal evolution
▼
Show Figures
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited
MDPI and ACS Style
Saunus, J.M.; McCart Reed, A.E.; Lim, Z.L.; Lakhani, S.R. Breast Cancer Brain Metastases: Clonal Evolution in Clinical Context. Int. J. Mol. Sci. 2017, 18, 152. https://doi.org/10.3390/ijms18010152
AMA Style
Saunus JM, McCart Reed AE, Lim ZL, Lakhani SR. Breast Cancer Brain Metastases: Clonal Evolution in Clinical Context. International Journal of Molecular Sciences. 2017; 18(1):152. https://doi.org/10.3390/ijms18010152
Chicago/Turabian StyleSaunus, Jodi M.; McCart Reed, Amy E.; Lim, Zhun L.; Lakhani, Sunil R. 2017. "Breast Cancer Brain Metastases: Clonal Evolution in Clinical Context" Int. J. Mol. Sci. 18, no. 1: 152. https://doi.org/10.3390/ijms18010152
Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.
Search more from Scilit